Dark Genome Therapeutics Market Size, Share and Trends Analysis, By Therapeutic Modality (Murine, Chimeric, Humanized, and Fully Human), By Target Type (In Vivo and Ex Vivo), By Development Stage, By Application (Hospitals, Specialty Clinics, Research & Academic Institutes, and Pharmaceutical & Biotechnology Companies), and By Region, Forecast 2025-2032

Dark Genome Therapeutics Market Overview and Key Insights:

The dark genome therapeutics market size reached USD 2,155.7 million in 2024 and is expected to register a revenue CAGR of 23.8% during the forecast period. The dark genome, particularly non-coding RNAs, shows potential for the development of new treatments. These techniques seek to restore cellular homeostasis and slow disease progression by altering gene expression patterns. Ongoing research aims to uncover disease-specific non-coding RNA signatures and create targeted therapies for a variety of illnesses.

Market Drivers:

Rising prevalence of chronic diseases is a key driver of revenue growth in the dark genome therapeutics market. According to the Cystic Fibrosis Foundation, cystic fibrosis affects about 40,000 children and adults in the United States (an estimated 105,000 people have been diagnosed with the disease in 94 countries), and it can affect people of all races and ethnicities. Idiopathic pulmonary fibrosis (IPF) is the most prevalent form of idiopathic interstitial lung disease. More than 250,000 Americans have PF and ILD. The frequency of PF and ILD is on the rise, with over 50,000 new cases identified each year.

Advancements in genomics and Next-Generation Sequencing (NGS) is another key driver driving the market revenue growth over the forecasted period. Recent breakthroughs in NGS technology have thrown light on annotating genomic dark matter and assigning biological functions to a wide range of human genome regions, including promoters, enhancers, repressors, transcription factor binding sites, and other regulatory components. NGS technology has also sped up the process of detecting disease-causing DNA anomalies in the human genome by screening the entire genome for non-coding alterations with regulatory benefits.

On November 2024, Dante Genomics, a global pioneer in genomics and personalized medicine, has announced that it will begin incorporating Generative AI elements into its initial product, the Dante Labs Whole Genome Platform. This achievement marks a big step forward in the company’s objective to make genomic data more actionable and accessible to both researchers and individuals. The endeavor is consistent with Dante Genomics’ overall mission of providing scalable, user-friendly tools for decoding the complexity of the human genome.

Market Opportunity:

Emergence of RNA-targeted therapies and epigenetic modulators acts as an opportunity for the dark genome therapeutics market. Long non-coding RNAs (lncRNAs) are emerging as promising therapeutic targets due to their extensive interaction networks and critical roles in human development and disease. A range of therapeutic approaches targeting lncRNAs has been developed, including the introduction of synthetic lncRNAs, manipulation of genomic loci, inhibition at both transcriptional and post-transcriptional levels, and interference with secondary structure formation or protein binding. These methods utilize tools such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), and CRISPR-Cas9 genome editing. Additionally, locked nucleic acid GapmeRs (LNA GapmeRs), antagoNATs (inhibitors of natural antisense transcripts), as well as catalytic molecules like deoxyribozymes and ribozymes, are under active investigation.

Recent Trends:

Emerging trends include advanced functional annotation of non-coding regions, CRISPR-based gene editing and epigenome editing, artificial intelligence and machine learning in genomic data, and synthetic biology and RNA engineering.

The fast introduction of the CRISPR/Cas9 nuclease system as a simple genome editing platform has transformed genome editing tools for studying the non-coding genome. To investigate non-coding regions, CRISPR-based genome editing relies on endogenous DNA repair processes that are activated by a CRISPR-associated nuclease-induced double strand break. CRISPR-based genome editing tools have provided a variety of ways for studying non-coding genomes, including both loss-of-function and gain-of-function approaches.

Restraints & Challenges:

Circulating lncRNAs present issues in terms of sensitivity and specificity for certain disorders, which can result in false negatives or positives. The translation of lncRNA-based therapeutics into clinics is still in its early stages, with considerable hurdles such as nonspecific immune responses, low specificity, and targeted administration.

When compared to protein coding regions, there is still a dearth of methodological research that can corroborate and aid in the incorporation of non-coding sequences into gene therapy.  This lack of understanding of how non-coding elements influence transgenic expression and their role in gene regulation has hampered the development of effective therapeutic techniques to maintain transgene activity in vivo.

Therapeutic Modality Segment Insights and Analysis:

Based on the therapeutic modality, the dark genome therapeutics market is segmented into Antisense Oligonucleotides (ASOs), small molecules, oligonucleotide vaccines, and monoclonal antibodies.

Monoclonal antibodies segment contributed the largest market share in 2024. The use of monoclonal antibodies is emerging as a highly promising and rapidly developing scenario for the treatment of viral, autoimmune, and tumor illnesses. The quest for diagnostic and therapeutic antibodies is currently based on in vitro screening methods such as phage and yeast display technology. Antibody generation is an important stage in preclinical and clinical studies. The stability and flexibility of antibodies, as well as their effector functions, are critical elements in determining immunoglobulins’ suitability for the development of therapeutic mAbs.

Target Type Segment Insights and Analysis:

Based on the target type, the dark genome therapeutics market is segmented into Long Non-Coding RNAs (lncRNAs), LINE-1 Reverse Transcriptase (LINE-1 RT), and Human Endogenous Retroviruses (HERVs).

Long non-coding RNAs (lncRNAs) segment contributed the largest market share in 2024. Long non-coding RNAs (lncRNAs) are ubiquitous transcripts with over 200 nucleotides and no obvious coding potential. lncRNAs are thought to play important regulatory roles in a variety of essential biological processes at the transcriptional, post-transcriptional, and epigenetic levels. In addition to serving as diagnostic markers, lncRNAs are being studied for cancer treatment. LncRNAs show considerable promise for innovative therapeutic uses and should thus be thoroughly studied in future studies. For example, because the secondary structures of lncRNAs are critical to their functions, research into their architectures is warranted.

On September 2024, HAYA Therapeutics, SA, a biotechnology company that pioneered precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, has announced a multi-year agreement with Eli Lilly and Company to use HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. To treat these chronic illnesses, the partners will find various therapeutic targets based on regulatory genome-derived RNAs.

Application Segment Insights and Analysis:

Based on the application, the dark genome therapeutics market is segmented into in cancer, autoimmune diseases, fibrotic diseases, neurodegenerative disorders, and others.

Cancer segment contributed the largest market share in 2024. According to the American Cancer Society, estimates for pancreatic cancer in the United States in 2025 are: pancreatic cancer will be diagnosed in around 67,440 persons (34,950 males and 32,490 women). Pancreatic cancer kills approximately 51,980 persons (27,050 men and 24,930 women). Pancreatic cancer has an average lifetime risk of one in 56 males and one in 60 women.

On May 2025, RyboDyn, Inc., a biotechnology firm developing first-in-class immunotherapies for the dark proteome, has expanded its strategic partnership with Moffitt Cancer Center, a global leader in cancer care and research. The collaboration intends to speed the development of immunotherapies that target novel, cancer-specific proteins discovered by RyboDyn’s proprietary sequencing and AI-driven target discovery platform, RyboCypher.

Geographical Outlook:

Dark genome therapeutics market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Dark Genome Therapeutics Market:

North America is registered to have largest market share in dark genome therapeutics market in 2024. This is mainly due to the rising prevalence of chronic diseases, advancements in genomics and Next-Generation Sequencing (NGS), and increased funding from governments and venture capitalists. According to the American Cancer Society, primary liver cancer and intrahepatic bile duct cancer in the United States in 2025 are an estimated 42,240 new cases (28,220 in men and 14,020 in women) will be diagnosed. These tumours will die around 30,090 people, including 19,250 males and 10,840 women. Every year, about 800,000 people are diagnosed with this cancer around the world. Liver cancer is also the biggest cause of cancer death worldwide, accounting for over 700,000 deaths each year.

On September 2024, HAYA Therapeutics, SA, a biotechnology company that pioneered precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, has announced a multi-year agreement with Eli Lilly and Company to use HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. To treat these chronic illnesses, the partners will find various therapeutic targets based on regulatory genome-derived RNAs.

Asia Pacific Dark Genome Therapeutics Market:

Asia Pacific is registered the fastest growth rate during the forecasted period. The region is boosted by advancements in genomics and Next-Generation Sequencing (NGS) and increased funding from governments and venture capitalists. Japan has a thriving scientific community that has made significant groundbreaking contributions to the science of genetics. These include early high-throughput DNA sequencers, genome-wide association analysis, and integrated genomic databanks.
On April 2025, Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, has announced a collaborative deal with Astellas Pharma, a multinational life sciences firm. Chromatin Bioscience’s chromatinLENS platform identifies gene regulatory regions in the dark genome and allows for the logical construction of synthetic promoters customized to specific applications. The platform has a wide range of applications, including pharmaceuticals, agritech, industrial biotechnology, and bioprocessing.

Europe Dark Genome Therapeutics Market:

Europe is to register a considerable market share during the forecasted period. This is mainly driven by advancements in genomics and Next-Generation Sequencing (NGS), emergence of RNA-targeted therapies and epigenetic modulators, and Integration of AI and machine learning in genomics. Furthermore, increased funding from governments and venture capitalists is also augmenting the growth of the market in the region.

For instance, on December 2024, HERVolution Therapeutics ApS, a dark genome-focused biotechnology business creating immunotherapies to treat aging-related disorders, announced today a USD 11.7 million Series A funding round to push its main assets into clinical trials. Serum Institute of India (SII) led the investment round, which included participation from the European Innovation Council (EIC) Fund and other investors.

Competition Analysis:

The dark genome therapeutics market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the dark genome therapeutics market report are:

• ROME Therapeutics
• HERVolution Therapeutics 
• HAYA Therapeutics
• Nucleome Therapeutics
• Enhanc3D Genomics Ltd
• NextRNA Therapeutics
• Amaroq Therapeutics
• Lucid Genomics GmbH
• NonExomics, LLC
• UbiVac

Strategic Developments in Dark Genome Therapeutics Market:

• In May 2025, HAYA Therapeutics, SA, a biotechnology business that pioneers precision RNA-guided regulatory genome targeted medicines that reprogram disease-driving cell states for rare, common, chronic, and age-related disorders, has announced a Series A fundraising round of USD 65 million. The funding will help HAYA speed the clinical development of its primary long non-coding RNA (lncRNA) candidate HTX-001 in heart failure, as well as the continuous expansion of its RNA-guided regulatory genome pipeline development engine.
• In August 2024, Bayer and NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to treat long non-coding RNA (lncRNA)-driven diseases, have announced a collaboration and license agreement to develop small molecule therapeutics targeting lncRNAs in oncology. lncRNAs are a broad class of therapeutic targets that recruit RNA-binding proteins (RBPs) to drive pathogenic processes in many disorders. Disrupting lncRNA-RBP interactions with small compounds is a novel technique for developing a new class of therapeutic medicines.
• In October 2022, Nucleome Therapeutics Limited, a biotechnology business that decodes the dark matter of the human genome to create first-in-class precision therapeutics, has announced the completion of an oversubscribed GBP 37.5 million Series A fundraising round. The funding will be used to improve the company’s autoimmune disease programs, expand its dark genome atlas, and further develop its groundbreaking platform. Nucleome’s innovative platform combines cutting-edge 3D genome technology and machine learning to shed light on these variants by directly correlating genes to diseases and mapping pathways with unparalleled precision for drug discovery.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of the Dark Genome Therapeutics Market Report:

The Dark Genome Therapeutics market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Therapeutic Modality Outlook (Revenue, USD Million; 2022-2032)
  • Antisense Oligonucleotides (ASOs)
  • Small Molecules
  • Oligonucleotide Vaccines
  • Monoclonal Antibodies

• Target Type Outlook (Revenue, USD Million; 2022-2032)
  • Long non-coding RNAs (lncRNAs)
  • LINE-1 Reverse Transcriptase (LINE-1 RT)
  • Human Endogenous Retroviruses (HERVs)

• Development Stage Outlook (Revenue, USD Million; 2022-2032)
  • Preclinical
  • Clinical
  • Post Clinical

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Cancer
  • Autoimmune Diseases
  • Fibrotic Diseases
  • Neurodegenerative Disorders
  • Others

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Dark Genome Therapeutics market report